{{ galleryProps.activeIndex + 1 }}/1
On request
Description
Profile Type: Business Offer
POD Reference: BORS20250318025
Term of Validity: 28 June 2025 - 28 June 2026
Company's Country: Serbia
Type of partnership: Commercial agreement, Investment agreement
Targeted Countries: Montenegro, Sweden, North Macedonia, Croatia, Serbia, Bosnia and Herzegovina, Slovenia
General information
Short Summary
Personalised pharmacotherapy goes beyond the trial-and-error approach to prescribing medicines by
tailoring treatment to the unique characteristics of each patient. We achieve this by combining
advanced laboratory methods of medical biochemistry…
Profile Type: Business Offer
POD Reference: BORS20250318025
Term of Validity: 28 June 2025 – 28 June 2026
Company's Country: Serbia
Type of partnership: Commercial agreement, Investment agreement
Targeted Countries: Montenegro, Sweden, North Macedonia, Croatia, Serbia, Bosnia and Herzegovina, Slovenia
General information
Short Summary
Personalised pharmacotherapy goes beyond the trial-and-error approach to prescribing medicines by
tailoring treatment to the unique characteristics of each patient. We achieve this by combining
advanced laboratory methods of medical biochemistry with insights from clinical studies and
observations. Through detailed patient characterisation, we assist physicians in selecting the drug and
dosage that offer the highest likelihood of successful treatment outcomes.
Full Description
We perform genetic, biochemical, and other laboratory analyses to characterize patients and develop
treatment algorithms that translate these measurements into actionable treatment guidelines. Our core
technique is chromatography combined with tandem mass spectrometry, which offers high sensitivity,
accuracy, and precision for measuring drug concentrations in blood samples. This analysis helps
determine whether a dose is appropriate and provides physicians with the necessary data to adjust it for
optimal efficacy and safety. Beyond measuring drug levels, our algorithm assesses daily variations in
drug concentration, enabling a more comprehensive analysis of drug exposure. One limitation of this
method is that it only becomes available a few weeks after treatment begins and cannot predict the
appropriate dose beforehand. To address this, we integrate predictive algorithms based on genetic,
anthropometric, and biochemical data. These models estimate drug metabolism, renal and liver
function, and account for confounding factors such as inflammation, comorbidities, and polypharmacy.
This approach helps guide initial dosing, preventing errors at the start of treatment, and can later be
validated through therapeutic drug monitoring.
Business Model & Market Segmentation
We operate on a B2B and B2B2C model, primarily serving physicians as direct users. Since these
physicians always work within legal entities, our market segmentation is based on the type of
institution, including:
· University Medical Centers
· Public Psychiatric Hospitals
· Private Psychiatric Hospitals
· Private Psychiatric Practices
Our economic buyers include:
· Pharmaceutical companies (particularly those focused on drugs with a narrow therapeutic
index)
· Health insurance companies
· Healthcare organizations
· Patients or their families
We offer both individual sales and subscription/loyalty programs for larger healthcare facilities.
Currently, we operate exclusively in Serbia, with plans to expand into neighboring markets in the near
future.
Advantages and Innovations
We have extensive experience with mass spectrometry and validated protocols for quantifying most
drugs affecting the nervous system that are registered in Serbia. Additionally, we can validate similar
protocols for any drug or compound required by the market within a few weeks. Our wide network of
partner laboratories enables sample collection across major Serbian cities, while our accredited central
laboratory in Belgrade ensures we provide valid biochemical reports to healthcare professionals. Our
entire analysis process, from requisition to reporting, is automated through custom-made software. As a leader in neurological and psychiatric research, our reputation in Southeastern Europe is unmatched.
This, combined with our scalable and flexible infrastructure, positions us for rapid expansion into larger
markets.
Our key competitive advantage is our deep expertise in pharmacokinetics. We utilize proprietary
algorithms to transform single-point drug concentration measurements into predictive models that
account for daily variability and fluctuations over time. This allows us to offer a more comprehensive
understanding of drug exposure and deliver superior clinical guidance. Ultimately, our therapeutic drug
monitoring service surpasses even elite high end laboratories worldwide in quality and precision.
Stage of Development
- Already on the market
Sustainable Development Goals
- Goal 3: Good Health and Well-being
IPR status
- IPR applied but not yet granted
Partner Sought
Expected Role of a Partner
We are actively seeking commercial partners for the distribution, clinical integration, and commercialization of our therapeutic drug monitoring (TDM) and dose optimization service. Ideal partners include:
Private and public healthcare providers (hospitals, clinics, psychiatric institutions, and diagnostic laboratories),
Providers of laboratory diagnostic services who can integrate our chromatographic-MS/MS analysis and/or genetic screening into their offerings,
Pharmaceutical companies interested in pharmacovigilance, real-world evidence, and supporting safe drug use in complex patient populations,
Digital health platforms and medical software providers interested in integrating our algorithmic models into eHealth systems.
Commercial partners would support:
Localized business development and sales targeting specialized physicians (psychiatrists, oncologists, neurologists, etc.),Onboarding of institutional users, including integration with their current lab or clinical workflows, Training and technical implementation, ensuring effective use of treatment guidelines produced by our analysis, Navigating regulatory and reimbursement pathways in target countries.
We welcome partnerships with research institutes, hospitals, clinical centers, universities, and biotech SMEs to co-develop and pilot innovations in the following areas:
– Therapeutic drug monitoring in chronic and psychiatric conditions,
– Personalized medicine through integration of genetic, metabolic, and real-world data,
– AI-driven clinical decision support, particularly in polypharmacy and multimorbidity,
– Pharmacogenomics and biomarker discovery to improve drug safety and efficacy.
We are actively interested in joint research proposals, especially under Horizon Europe, EU4Health, and Digital Europe calls, including:
– Personalised Health and Care,
– Next Generation AI in health decision-making,
– Real-world data & clinical decision support, and
– Integration of genomics into clinical practice.
We are open to discussions with early-stage health tech and life sciences investors who recognize the value of next-generation precision diagnostics and therapeutic personalization.
Our solution addresses a growing unmet need for real-time, individualized dose management, and is positioned to scale across regulated healthcare markets.
We are seeking investment to:
– Scale laboratory and processing capacity,
– Expand algorithm validation across broader drug classes,
– Strengthen clinical partnerships in new EU markets,
– Accelerate digital platform integration (e.g. via APIs with hospital systems),
– Pursue regulatory and reimbursement processes in priority countries.
We welcome equity investment offers, co-development funding, or innovation grant matchmaking through EEN investor and funder networks.
Type and Size of Partner
- SME 11-49
- SME 50 – 249
- SME <=10
Type of partnership
- Commercial agreement
- Investment agreement
Dissemination
Technology keywords
- 06001014 – Neurology, Brain Research
- 06001020 – Physiotherapy, Orthopaedic Technology
- 06001005 – Diagnostics, Diagnosis
Market keywords
- 05005022 – Other clinical medicine
- 05001005 – Molecular diagnosis
- 05007002 – Pharmaceuticals/fine chemicals
- 05003001 – Therapeutic services
- 05007007 – Other medical/health related (not elsewhere classified)
Sector Groups Involved
- Health
Ponuda ID #28106
Request for quote!
Categories:
Business cooperation
Sektor saradnja:
Zdravstvo i njega
Country:
Srbija
Latest ads
Innovative Hungarian manufacturer of allergen-free chocolates and bars offers international distribution and private-label co-operation
On request
Prehrambena industrija
Mađarska
German SME in the field of industrial screwdriving assembly technology is looking for subcontractors in several countries of the European Union
On request
Metalna industrija
Germany
Turkish SME offers privacy-preserving IoT people-counting and retail analytics platform for international deployment
On request
Telekomunikacije i informatika
Turska
Cloud-native SCADA/IIoT solution from Serbia enables manufacturers to achieve over 10% higher efficiency and seamless integration across industrial environments
On request
Telekomunikacije i informatika
Srbija
Business panel - specialized business buying and selling web platform / ITD Marketing d.o.o. Banja Luka / Miše Stupara 4 / 78 000 Banja Luka
Copyright © 2025. Poslovni pano / Sva prava zadržana